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Targeting large transmembrane molecules, including receptor tyrosine kinases, is a major pharmacological challenge.
Specific oligonucleotide ligands (aptamers) can be generated for a variety of targets through the iterative evolution of
a random pool of sequences (SELEX). Nuclease-resistant aptamers that recognize the human receptor tyrosine kinase
RET were obtained using RET-expressing cells as targets in a modified SELEX procedure. Remarkably, one of these
aptamers blocked RET-dependent intracellular signaling pathways by interfering with receptor dimerization when the
latter was induced by the physiological ligand or by an activating mutation. This strategy is generally applicable to
transmembrane receptors and opens the way to targeting other members of this class of proteins that are of major
biomedical importance.
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Introduction
The identiﬁcation of tumor-speciﬁc molecular markers is a
powerful tool in cancer diagnostics, and the targeting of
tumor-speciﬁc pathways is the best hope for developing non-
toxic and efﬁcient anticancer therapies. Targeting of cancer
cellsreliesonthedevelopmentofmolecularbeacons,suitedfor
in vivo applications, that are endowed with the required
afﬁnity,speciﬁcity, andfavorable pharmacokinetic properties.
With the systematic evolution of ligands by exponential
enrichment(SELEX)technology[1,2],speciﬁcmacromolecular
ligands—aptamers—can be generated by screening very large
pools of oligonucleotides containing regions of random base
composition with reiterated cycles of enrichment and ampli-
ﬁcation. At each cycle, the individual oligonucleotides with
afﬁnity for the desired target are kept, those with afﬁnity for
the sham target are rejected, and the population is enriched in
oligonucleotides that distinguish between sham and real
target. Aptamers that recognize a wide variety of targets, from
small molecules to proteins and nucleic acids, and from
cultured cells to whole organisms, have been described
[3,4,5,6,7,8,9,10]. These oligonucleotides generally meet the
requirements for in vivo diagnostic and/or therapeutic
applications: Besides their good speciﬁcity and afﬁnity, they
are poorly immunogenic, and the SELEX technology can now
accept chemically modiﬁed nucleotides for improved stability
in biological ﬂuids [11]. Conspicuously, less than ﬁfteen years
after the ﬁrst applications of the technique, several lead
compounds, including an anti-vascular endothelial growth
factor aptamer [12], are currently under clinical trials [13].
Receptor tyrosine kinases (RTKs) are involved in a variety
of signaling processes that regulate cell growth and prolifer-
ation and in several cancers [14]. RTKs are privileged targets
for cancer therapy, which is underscored by the promising
outcome of clinical trials with small molecules or antibody
inhibitors [14]. In the present study, we validated a general
strategy to target transmembrane receptors by SELEX. The
RET (rearranged during transfection) RTK is physiologically
stimulated by any member of the glial cell line-derived
neurotrophic factor (GDNF) family [15,16]. Germline muta-
tions in the RET gene are responsible for constitutive
activation of the receptor and for inheritance of multiple
endocrine neoplasia (MEN) type 2A and 2B syndromes and of
familial medullary thyroid carcinoma [17,18,19,20].
Mutations in the extracellular domain of RET, responsible
for MEN2A syndrome, lead to constitutive dimerization of
two mutated RET molecules. Conversely, a single point
mutation, within the RET catalytic domain, that causes the
MEN2B syndrome, involves an intramolecular mechanism to
convert RET into a dominant transforming gene. Therefore,
RET constitutes a model system of choice [20], in that the
transforming mutations located in the extracellular domain
simplify the issue of intracellular accessibility for a molecule
targeting the receptor mutated in the extracellular domain
(in its monomeric or dimeric form) and might provide
alternative models (e.g., RET with mutations of the 2B kind)
for controls or to elucidate the mode of target recognition.
Here we adopted a whole-cell SELEX strategy to target RET
in a complex environment that is expected to expose a native
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Open access, freely available online PLoS BIOLOGYprotein to the selection procedure, thus best mimicking in
vivo conditions. We obtained aptamers that not only
recognize the extracellular domain of RET, but also block
RET downstream signaling and subsequent molecular and
cellular events. The fact that aptamers with antioncogenic
activity were isolated in the absence of a speciﬁc selective
pressure suggests that our method could be used to identify
active macromolecules with potential therapeutic interest
against other transmembrane receptors.
Results
A library of 29-ﬂuoropyrimidine (29F-Py), nuclease-resistant
RNAs was subjected to a differential SELEX protocol against
intact cells expressing different forms of the human RET
oncogene (Figure 1). For the selection step, PC12 cells were
used that express the human RET
C634Y mutant receptor
(PC12/MEN2A). RET
C634Y is mutated in the extracellular
domain and forms spontaneously active homodimers on the
cell surface, which induces biochemical and morphological
changes that mirror the RET-dependent human pheochro-
mocytoma phenotype of MEN2 syndromes [21]. The counter-
selection necessary to avoid selecting for aptamers that
nonspeciﬁcally recognized the cell surface included a ﬁrst
step against parental PC12 cells in order to eliminate
nonspeciﬁc binders of the PC12 cell surface, followed by a
second counterselection step against PC12/MEN2B cells that
expressed an allele of RET (RET
M918T) mutated in the
intracellular tyrosine kinase domain. PC12/MEN2B and
PC12/MEN2A cells have a similar morphology, but the
extracellular domain of the RET
M918T receptor is identical
to the wild type and, in the absence of the ligand and co-
receptor, remains monomeric. This step was originally aimed
at selecting aptamers that recognize speciﬁcally the dimeric
form of the extracellular domain.
After 15 rounds of selection, the pool of remaining
sequences bound PC12/MEN 2A cells in a saturable manner
with an apparent Kd approximating 100 nM. From this pool,
67 sequences were cloned and analyzed. Two individual
sequences (D14 and D12) dominated the selection and
constituted together more than 50% of the clones, four
other sequences represented together 25% of the clones, and
eight sequences were present only once. As is often the case
for a selection against a complex target [7,22] (and in contrast
to in vitro SELEX on puriﬁed proteins) we found almost no
similarity among sequences, except for clones D24 and D4,
w h i c hs h a r e dc o m m o ns e q u e n c em o t i f sa n ds t r u c t u r e
prediction (Figure 2A).
We assessed binding to PC12/MEN2A cells of all individual
aptamers that were found more than once and also of some
unique sequences (including D4 and D24). Several sequences
bound PC12/MEN2A cells with apparent Kd values ranging
from 30 to 70 nM (Figure 2B and unpublished data), but not
parental PC12, rat-derived bladder carcinoma (NBTII), or
human cervical carcinoma (HeLa) cells (Figure 2C and
unpublished data). As a ﬁrst attempt to deconvolute the
complex pool of winning aptamers, we ﬁrst produced a
recombinant fragment of RET, EC-RET
C634Y [23], but all
attempts to identify in the winning pool aptamers binding to
EC-RET
C634Y were fruitless. Likewise, SELEX against this
puriﬁed EC-RET
C634Y protein gave rise to aptamers unable to
recognize the PC12/MEN2A cells, suggesting that they did not
bind to the RET protein present in its native conformation
on the cell surface. Consequently, we screened the winning
pool of aptamers for the ability to interfere with the
biological activity of RET. To this end, we used an in vitro
cell system in which we assessed the capability of each
aptamer to inhibit RET
C634Y autophosphorylation and
receptor-dependent downstream signaling. Mutant RET
C634Y,
expressed in PC12/MEN2A cells, forms homodimers on the
cell surface that cause constitutive activation of its tyrosine
kinase activity [24] and induce several downstream signaling
cascades, including the activation of extracellular signal-
regulated protein kinase (ERK) [25]. As previously reported
[25], levels of phosphorylated RET and ERK were constitu-
tively high in untreated PC12/MEN2A cells due to the
presence of the active RET
C634Y allele. Surprisingly, some of
the tested aptamers inhibited RET
C634Y and ERK phosphor-
ylation, compared to the control starting pool and to the
other aptamers (Figure 3A and unpublished data). In all
experiments, inhibition of phosphorylation was more rapid
and quantitative for ERK than for RET
C634Y. We believe that
this is due to a different sensitivity to changes in RET tyrosine
kinase activity of the two processes and/or to differences in
the half-lives of the phosphorylated forms of the two proteins
[26]. In a dose-response experiment (Figure 3B, left panel),
the best inhibitor, D4, was effective at a concentration of
200 nM to inhibit RET
C634Y autophosphorylation up to 70%
and to drastically reduce ERK phosphorylation. Time-activity
studies showed that the treatment of PC12/MEN2A cells at
Figure 1. Schematic Protocol for the Selection of PC12/MEN2A Cell-
Specific Aptamers
A pool of 29F-Py RNAs was incubated with suspended parental PC12
cells (Counterselection 1). Unbound sequences were recovered by
centrifugation and incubated with adherent PC12/MEN2B cells
(Counterselection 2). Unbound sequences in the supernatant were
recovered and incubated with adherent PC12/MEN2A cells for the
selection step (Selection). Unbound sequences were discarded by
several washings, and bound sequences were recovered by phenol
extraction. Sequences enriched by the selection step were ampliﬁed
by RT-PCR and in vitro transcription before a new cycle of selection.
DOI: 10.1371/journal.pbio.0030123.g001
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Aptamer Inhibition of RET RTKFigure 3. Effect of Selected Aptamers on RET
C634Y Activity
(A) PC12/MEN2A cells were either left untreated or treated for 16 h
with 150 nM of the indicated RNA aptamer, or the starting RNA pool
(pool). Cell lysates were immunoblotted with anti-(phospho)-ERK
(pErk), then stripped and reprobed with anti-ERK (Erk) to conﬁrm
equal loading. Values below the blots indicate signal levels relative to
untreated controls.
(B) PC12/MEN2A cells were treated for 1 h with increasing amounts
of D4 (left blots) or with 200 nM D4 for the indicated incubation
times (right blots). Cell lysates were immunoblotted with anti-(Tyr-
phosphorylated)-RET (pRet) or anti-(phospho)-ERK (pErk) antibod-
ies, as indicated. To conﬁrm equal loading the ﬁlters were stripped
and reprobed with anti-RET (Ret) or anti-ERK (Erk) antibodies,
respectively.
In (A) and (B), ‘‘C’’ indicates mock-treated cells. Quantitations were
done on the sum of the two RET- or ERK- speciﬁc bands, and values
are expressed relative to the control, arbitrarily set to 1. Standard
deviations are indicated (n = 4).
DOI: 10.1371/journal.pbio.0030123.g003
Figure 2. Predicted Structure and Association Constants of D4 and D24
(A) Comparison of a secondary structure prediction for the D4 and
D24 aptamers. Structures were predicted using MFOLD software ver-
sion 3.1 (available at http://www.bioinfo.rpi.edu/applications/mfold/).
(B) Binding curve of the D4 aptamer on PC12/MEN2A. D4 was
32P-radiolabeled and incubated at different concentrations on cell
monolayers. The background binding value for a D4 scrambled
sequence is subtracted from every data point. Scatchard analysis
(inset) was used for the evaluation of the binding constant.
(C) Binding of the
32P-labeled D4 aptamer to several cell lines
expressing (or not) human RET. Binding was performed on the cell
lines indicated in the same condition at 50 nM, and the results are
expressed relative to the background binding detected with the
starting pool of sequences used for selection. Expression of RET
could not be detected by Western blot in HeLa, NBTII, PC12wt and
NIH3T3 cells, whereas PC12/MEN2A and NIH3T3/MEN2A express
RET
C634Y and PC12/MEN2B and NIH3T3/MEN2B express RET
M918T.
DOI: 10.1371/journal.pbio.0030123.g002
PLoS Biology | www.plosbiology.org April 2005 | Volume 3 | Issue 4 | e123 0699
Aptamer Inhibition of RET RTK200 nM for 1 h was sufﬁcient to signiﬁcantly inhibit RET
C634Y
autophosphorylation and to drastically reduce ERK phos-
phorylation (Figure 3B, right panel).
Comparison of the predicted structures of D4 and of the
related clone D24 (Figure 2A) suggests that a conserved stem-
internal loop-stem is crucial for binding. Consistently, we
found that replacing the apical loop with a stable tetraloop
(UUGC) or deleting nucleotides not included in the con-
served structure did not signiﬁcantly affect binding of D4 to
PC12/MEN2A cells (unpublished data). However, only the full-
length D4 inhibits RET
C634Y signaling, demonstrating that
binding is necessary but not sufﬁcient for inhibition. A 29F-Py
RNA oligonucleotide of identical composition but with a
scrambled sequence (D4Sc) was ineffective for both binding
and inhibition.
The D4 aptamer bound to PC12/MEN2A with an estimated
apparent Kd of 35 6 3 nM (Figure 2B), but also to PC12/
MEN2B cells (Figure 2C and unpublished data), suggesting
that one of the counterselection steps employed in the SELEX
procedure was ineffective in this case. The D4 aptamer bound
to transfected NIH3T3 cells expressing at similar levels the
two mutant forms (RET
C634Y and RET
M918T) of the RET
receptor (NIH/MEN2A and NIH/MEN2B, respectively [Figure
2C; see also below]). Binding was dependent on expression of
human RET, as D4 did not recognize parental untransfected
PC12, NIH3T3 cells, or other cell lines, including rat NBTII,
human HeLa cells, and mouse MN1 (Figure 2C and
unpublished data). Interestingly, the latter, a mouse motor
neuron-neuroblastoma fusion cell line, expresses the mouse
RET
wt, suggesting some species-speciﬁcity in RET recognition
by D4. Finally, D4 bound a human neuroblastoma cell line
(SK-N-BE) that naturally expresses endogenous RET (L.
Cerchia et al., personal communication). Consistently with
what was observed for the pool of winning aptamers, D4 was
unable to bind the puriﬁed EC-RET
C634Y protein (unpub-
lished data), thus supporting the speciﬁcity for the mem-
brane-bound RET.
We next determined whether D4 could inhibit wild-type
RET. Cells from a PC12-derived cell line expressing the
human wild-type RET (PC12/wt) were stimulated with a
mixture containing GDNF and soluble GDNF family receptor
a1 (GFRa1), and either treated with the D4 aptamer or with
the starting pool of 29F-Py RNA as a negative control. As
shown in Figure 4A, the D4 aptamer, but not the control RNA
pool, strongly inhibited GDNF-induced phosphorylation of
RET (left panel) and of the downstream effector ERK (middle
panel). A similar inhibitory effect was observed in PC12-a1/wt
cells, a PC12-derived cell line that stably expresses both
human RET and GFRa1 (unpublished data). In contrast, D4
was inactive in inhibiting the signaling triggered by the
unrelated nerve growth factor (NGF) receptor tyrosine kinase
TrkA, thus indicating that D4-induced inhibition of ERK
phosphorylation was speciﬁc for RET intracellular signaling
(Figure 4A, right pane)
Although the D4 aptamer binds PC12/MEN2B cells, treat-
ing these cells with 200 nM D4 for 1 h (Figure 4B) or longer,
Figure 4. D4 Aptamer Inhibits RET
wt but Not RET
M918TActivity
(A) PC12/wt cells were treated for 10 min with GDNF (50 ng/ml) and soluble GFRa1 (1.6 nM), or 5 min with NGF (100 ng/ml), together with 200
nM of either the D4 aptamer or the starting RNA pool. ‘‘C*’’ indicates cells treated with GDNF and GFRa1 in the absence of aptamer.
(B) PC12/MEN2B cells were starved for 6 h and then treated for 1 h with 200 nM D4 or the starting RNA pool. Cell lysates were immunoblotted
with anti-(Tyr-phosphorylated)-RET or anti-(phospho)-ERK antibodies, as indicated (see Figure 3 legend).
In (A) and (B), ‘‘C’’ indicates mock-treated cells. Quantitations were done as in Figure 3, and relative abundances are expressed relative to
controls, arbitrarily set to 1. Standard deviations are indicated (n = 4).
DOI: 10.1371/journal.pbio.0030123.g004
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Aptamer Inhibition of RET RTKor at higher D4 concentrations (unpublished data), did not
interfere with signaling due to the monomeric RET
M918T.
This further conﬁrms that inhibition of ERK phosphorylation
is not a nonspeciﬁc effect of exposing the cells to the D4
aptamer. The kinase and the biological activities of RET
M918T,
although constitutive, are responsive to GDNF stimulation in
the presence of GFRa1 [27,28]. Similarly to the inhibition of
RET
wt activity, the treatment of PC12/MEN2B cells by D4
abolished the GDNF-dependent overstimulation of RET and
ERK phosphorylation (unpublished data). These data strongly
suggest that D4 inhibits exclusively the dimerization-depend-
ent RET activation.
We then searched for phenotypic effects of D4 on RET-
dependent cell differentiation and transformation. First we
measured neurite outgrowth in PC12-a1/wt cells following
GDNF stimulation. As shown in Figure 5, cells extended long
neurite-like processes in response to a 48-h exposure to
GDNF (Figure 5B) with respect to the nonstimulated control
cells (Figure 5A). Treatment of the cells with the D4 aptamer
(Figure 5C), but not with the D4Sc scrambled control
(Figure 5D), signiﬁcantly decreased the proportion of neurite
outgrowth (Figure 5E). To biochemically monitor differentia-
tion, we determined the levels of the nerve growth factor-
inducible protein (VGF) in cell extracts following 48 h of
treatment. VGF is an early gene that is rapidly induced by
both NGF and GDNF in PC12 cells [29]. As expected, in
GDNF-treated cells, VGF expression was stimulated and,
consistent with the phenotypic effects reported above,
treatment with D4, but not with D4Sc, kept the VGF levels
close to basal (Figure 5F).
Upon expression of either RET
C634Y or RET
M918T, NIH3T3
cells show drastic changes in their morphology [24]. We
treated NIH/MEN2A and NIH/MEN2B cells stably expressing
the RET mutants with D4 for 72 h, and analyzed the
Figure 5. D4 Aptamer Inhibits the GDNF-Induced Differentiation of PC12-a1/wt Cells
Cells were either left unstimulated (A), stimulated with GDNF (B), or with GDNF together with D4 or D4Sc (C and D, respectively). Following 48 h
of GDNF treatment, the percentage of neurite outgrowth was calculated. The data represent the average of three independent experiments and
are expressed as percentage of neurite-bearing cells/total cells analyzed (E). Following 48 h of treatment, cells were lysed and proteins
immunoblotted with anti-VGF antibodies. Equal loading was conﬁrmed by immunoblotting with anti-ERK antibodies as indicated (F).
DOI: 10.1371/journal.pbio.0030123.g005
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Aptamer Inhibition of RET RTKmorphological changes induced by the aptamer. As shown in
Figure 6, NIH/MEN2A and NIH/MEN2B cells have a spindle
shape, long protrusions, and a highly refractive appearance
(Figure 6B and 6E, respectively). As expected, D4-treated NIH/
MEN2A cells (Figure 6C) reverted to a ﬂat and polygonal
morphology similar to the parental NIH3T3, whereas no
morphological changes were observed in NIH/MEN2B
(Figure 6F), which is consistent with the notion that con-
stitutive signaling from RET
C634Y, but not from RET
M918,i s
inhibited by D4. On the other hand, treatment with D4Sc had
no effects on any cell line (Figure 6D and unpublished data).
Discussion
RTKs are involved in a variety of signaling pathways that
affect cell growth and differentiation. Targeting speciﬁcally
RTKs holds potential for dissecting the molecular mecha-
nisms of receptor function, but also for diagnosis and
therapeutics of cancer [14].
Here we employed a modiﬁed SELEX procedure to target
the RET RTK, and we obtained nuclease-resistant RNA
ligands capable of binding and inhibiting the protein on
the cell surface. Aptamers against recombinant heregulin 3
(HER3) RTK have been recently isolated and shown to inhibit
the heregulin-induced activation of the HER3/HER2 dimer
[30]. However, ﬁnding the most efﬁcient binders and
inhibitors is likely to generally rely on the recognition of
the target protein in its native state.
In the case of transmembrane receptors, whole-cell SELEX
offers the advantage of selecting molecules capable of
recognizing the target protein in its natural glycosylation
state and presented in its physiological environment. An
important drawback of this strategy is the lack of knowledge
of the identity and abundance of the effective targets and the
possibility that unwanted aptamers may dominate the
selection, preventing the emergence of the molecules of
interest. However, the abundance of the target protein and
an appropriate selection scheme might provide sufﬁcient
selective pressure to favor the wanted aptamers [10].
The D4 aptamer binds to different cell types, provided that
human RET is expressed on the cell surface, and speciﬁcally
inhibits both RET and ERK phosphorylation, strongly
suggesting that RET is the bona ﬁde target of D4. Interest-
ingly, aptamers isolated by whole-cell SELEX were unable to
bind puriﬁed EC-RET
C634Y and, conversely, aptamers coming
from the selection with puriﬁed EC-RET
C634Y were unable to
bind the membrane-bound RET. Thus, it is likely that D4
binding is dependent on the association of RET with the
cellular membrane, which might reﬂect changes in the
receptor’s conformation/modiﬁcation state or, alternatively,
might imply unidentiﬁed molecular components interacting
with RET at the cell surface. This latter possibility is
supported by a recent report demonstrating that the
presence of heparan sulfate glycosaminoglycan on the cell
surface is required for RET-dependent GDNF intracellular
signaling [31].
Our interpretation of the D4 aptamer’s mode of action
relies upon three observations: (1) D4 binds with similar
afﬁnities to cells expressing RET in a monomeric or dimeric
form; (2) D4 inhibits dimerization-dependent RET activation,
as a consequence either of GDNF stimulation of RET
wt or
RET
M918T or of constitutive dimerization of the RET
C634Y
mutant; and (3) D4 does not inhibit a monomeric form of
RET that is constitutively activated by a mutation in the
intracellular kinase domain (RET
M918T). These results taken
together are compatible with the notion that D4 acts by
interfering with the formation of a stable, active RET dimer,
regardless of whether dimerization is caused by the formation
of the RET/GDNF/GFRa1 complex or by the direct inter-
action of two mutated RET
C634Y proteins. This might occur
either by D4 binding to monomeric RET, which would
impede subsequent formation of the dimer, or by binding
directly to the dimer.
Differential whole-cell SELEX strategies (this work; see also
[5,7,8,10]) can be employed to identify new markers on the
surface of a given cell type, deﬁne the speciﬁcity of a cellular
state, and/or allow in vivo targeting for diagnostic and
therapeutic applications. The identiﬁcation of lead com-
pounds by reiterated afﬁnity selection on living cells appears
crucial when the molecular target is a membrane-bound or
large transmembrane protein for which the conformation is
frequently dictated by the interaction with other molecules,
including membrane constituents [31]. Given that several of
these proteins, as transmembrane receptors, integrins, and
adhesion molecules, are involved in cell proliferation,
apoptosis, and differentiation, aptamers for these targets
could be promising prognostic tools in human therapy for
Figure 6. D4 Aptamer Reverts the Transformed Morphology of NIH/
MEN2A Cells
NIH3T3-derived cell lines were either left untreated (A, B, and E) or
treated with D4 (C and F) or D4Sc (D), and the cells were maintained
in culture for 72 h. Each experiment was repeated a minimum of
three times.
DOI: 10.1371/journal.pbio.0030123.g006
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Aptamer Inhibition of RET RTKwidespread, devastating diseases such as cancer and neuro-
degeneration.
Materials and Methods
Cell culture and immunoblot analysis. Growth conditions for PC12
cells and derived cell lines were previously described [32]. NIH/
MEN2A and NIH/MEN2B cells were obtained from NIH3T3 cells
stably transfected with vectors expressing human RET
C634Y and
RET
M918T. To assess the effects of aptamers on RET activity, cells
(160,000 cells per 3.5-cm plate) were serum-starved for 2 h and then
treated with the indicated amount of RNA aptamers or the starting
RNA pool after a short denaturation-renaturation step. When
indicated, 2.5S NGF (Upstate Biotechnology, Lake Placid), GDNF
(Promega), or recombinant rat GFRa1-Fc chimera (R&D Systems,
Minneapolis, Minnesota, United States) were added to the culture
medium. Cell extracts and immunoblotting analysis were performed
as described [23]. The primary antibodies used were anti-RET (C-19),
anti-VGF (R-15), and anti-ERK1 (C-16) (all three, Santa Cruz
Biotechnology, Santa Cruz, California, United States); and anti-
(Tyr-phosphorylated) RET and anti-phospho-44/42 MAP kinase (also
indicated as anti-[phospho]-ERK) monoclonal antibodies (E10) (both
from Cell Signaling, Beverly, Massachusetts, United States). Four
independent experiments were performed.
Cell transformation and neurite outgrowth bioassay. PC12-a1/wtor
NIH3T3 cells were plated at equal density on 12-well culture plates.
Aptamers were added at 3 lM ﬁnal concentration to the growth
medium. To ensure the continuous presence of a concentration of at
least 200 nM, this treatment was renewed every 24 h, which takes into
accountthehalf-lifeoftheD4aptamerin10%serum(approximately6
h, unpublished data). At least 15 random ﬁelds were photographed
every 24 h with a phase-contrast light microscope. To evaluate the
effects of D4 on cell differentiation, cells were pretreated for 6 h with
400 nM D4 or D4Sc and then incubated with 50 ng/ml GDNF together
with 3 lM of the appropriate aptamer (see above). At 24 and 48 h of
GDNF stimulation, 50 cells per frame were counted and scored as
havingneuritesornot.Aneuritewasoperationallydeﬁnedasaprocess
outgrowth with a length more than twice the diameter of cell body.
Ex vivo SELEX. The SELEX cycle was performed essentially as
described [33]. Transcription was performed in the presence of 1 mM
29F-Py and a mutant form of T7 RNA polymerase (T7
Y639F, kind gift of
R. Souza) [11] was used to improve yields. 29F-Py RNAs were used
becauseoftheirincreasedresistancetodegradationbysericnucleases.
Thecomplexityofthestartingpoolwasroughly10
14.29F-PyRNAs(1–5
nmol)wereheatedat858Cfor5minin3mlofRPMI1640,snap-cooled
on ice for 2 min, and allowed to warm up to 37 8C before incubation
withthecells.Twocounterselectionstepswereperformedpercycle.To
avoid selecting for aptamers nonspeciﬁcally recognizing the cell sur-
face,thepoolwasﬁrstincubatedfor30minat378Cwith10
7PC12cells,
and unbound sequences wererecovered by centrifugation. These were
subsequently incubated with 10
7 adherent PC12/MEN2Bcells, express-
ing a human RET receptor mutated in the intracellular domain
(RET
M918T), and unbound sequences were recovered for the selection
phase. This step was meant to select sequences recognizing speciﬁcally
the human RET receptor mutated in the extracellular domain
(RET
C634Y) expressed on PC12/MEN2A cells. The recovered sequences
wereincubatedwith10
7adherentPC12/MEN2Acellsfor30minat378C
in the presence of nonspeciﬁc competitor RNA (total yeast RNA) and
recovered after several washings with 5 ml of RPMI by total RNA
extraction (Extract-All, Eurobio, Les Ulis, France).
During the selection process, we progressively increased the
selective pressure by increasing the number of washings (from one
for the ﬁrst cycle up to ﬁve for the last three cycles) and the amount of
nonspeciﬁc RNAcompetitor(100 lg/mlin thelastthree cycles),andby
decreasing the incubation time (from 30 to 15 min from round 5) and
the number of cells exposed to the aptamers (5310
6 in the last three
cycles). To follow the evolution of the pool we monitored the
appearance of four-base restriction sites in the population, which
reveals the emergence of distinct families in the population [34]. After
15 rounds of selection, sequences were cloned with TOPO-TA cloning
kit (Invitrogen, Carlsbad, California, United States) and analyzed.
Binding experiments. Binding of individual aptamers (or the
starting pool as a control) to PC12 cells and derivatives was performed
in 24-well plates in triplicate with 59-
32P-labeled RNA. 10
5 cells per
well were incubated with various concentrations of individual
aptamers in 200 ll of RPMI for 10 min at 37 8C in the presence of
100 lg/ml polyinosine as a nonspeciﬁc competitor. After extensive
washings (53500 ll of RPMI), bound sequences were recovered in 350
ll of SDS 0.6%, and the amount of radioactivity recovered was
normalized to thenumber ofcells by measuringthe proteincontent of
each well. Binding of individual sequences to different cell lines was
performed in the same condition at 50 nM only.
For the binding curve of D4 to PC12/MEN2A cells (see Figure 2B),
nonspeciﬁc binding was assessed using a 59-
32P-labeled naive pool of
29F-RNAs (i.e., the starting pool of the selection), and the background
values obtained were subtracted from the values obtained with the D4
aptamer. Apparent Kd values for each aptamers were determined by
Scatchard analysis according to the equation
[bound aptamer]/[aptamer] =  (1/Kd) 3 [bound aptamer]
þ ([T]tot/Kd) (1)
where [T]tot represents the total target concentration.
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